key: cord-0929373-50d2dv72 authors: Song, Amy; Nicholson, Cynthia; Maguiness, Sheilagh title: Recurrent reactive infectious mucocutaneous eruption (RIME) in two adolescents triggered by several distinct pathogens including SARS‐CoV‐2 and influenza A date: 2021-09-13 journal: Pediatr Dermatol DOI: 10.1111/pde.14780 sha: d1a94371c811c56975b0564c3a364cd87c1da6af doc_id: 929373 cord_uid: 50d2dv72 Reactive infectious mucocutaneous eruption (RIME) was proposed as new terminology to encompass postinfectious mucocutaneous eruptions. The term includes all postinfectious mucocutaneous eruptions such as the widely reported Mycoplasma pneumoniae‐induced rash and mucositis (MIRM). Very few reports in the literature regarding recurrent RIME are found. We present two adolescent cases of recurrent RIME that involve SARS‐CoV‐2 and influenza A where the latter is a newly reported infectious trigger; in both patients, the initial episode was likely triggered by Mycoplasma pneumoniae (MP) infection. Pediatric Dermatology SONG et al. He was treated with oral amoxicillin 500 mg and clobetasol propionate 0.05% ointment. Lip lesions resolved 12 days later. One and half years later, he presented with a 5-day history of headaches and malaise without fever or cough and 1 day of oral mucositis with a pinpoint rash on the neck and face. His younger brother had tested positive for influenza the day before. An influenza test was not performed given recent exposure history, type of symptoms which occurred during peak flu season months, and patient had not received seasonal flu vaccine. Physical examination showed erosions on the lips, erythematous papules on the lateral tongue, and ulcerations on the upper and lower gingival. Laboratory results showed elevated MP IgG and negative MP IgM titers. The suspected diagnosis for this episode was recurrent RIME, presumed to be due to influenza. Patient was given topical 0.05% clobetasol propionate ointment, azithromycin (500 mg × 2 days, 250 mg × 4 days), oseltamivir 75 mg, and a tapering course of oral prednisolone (50 mg × 3 days, 40 mg × 2 days, 30 mg × 2 days and 20 mg × 2 days). The lip lesions were almost completely healed after 10 days. Eleven months later, the patient presented again with oral mucositis. He reported a cough, fever, and body aches for 3 days preceding the eruption. Physical examination showed oral mucositis with mild desquamation on the lower lip. Hypopigmentation on the upper lip was found. Patient had a positive SARS-CoV-2 PCR test from the nasopharynx the week before the eruption. Given suspected recurrent RIME, no additional laboratory tests were performed. The most likely diagnosis was recurrent RIME, most likely due to SARS-CoV-2. He was treated with a tapering course of oral prednisolone (30 mg × 3 days, 20 mg × 3 days, 10 mg × 5 days), topical 0.05% clobetasol propionate ointment, and petrolatum ointment. An 18-year-old girl presented with 1 week of cough and fever fol- Rash and mucositis due to respiratory infections in pediatric patients has been recently described under the term reactive infectious mucocutaneous eruption (RIME) since many infectious pathogens have been implicated in the clinical presentation of postinfectious rash and mucositis. 3 RIME is distinct from EM and SJS due to its prominent mucositis with sparse cutaneous lesions, association with atypical pneumonia and younger patients as well as a better clinical prognosis than SJS. 2, 10 In this article, we present two cases of recurrent RIME. In the first case, the first episode was likely due to MP; the second due to group A streptococcus; the third likely due to influenza; and the fourth due to SARS-CoV-2. In the second case, the first was likely due to MP; the second due to influenza A; and the third due to an unknown infectious pathogen. We report episodes of recurrent RIME triggered by SARS-CoV-2 and influenza A, which to our knowledge are the first reports of influenza A triggering RIME. Thus, in cases of rash and mucositis associated with respiratory symptoms in a pediatric patient, we propose the importance of testing broadly for infectious pathogens including seasonal flu and SARS-CoV-2. In both patients, subsequent recurrent episodes revealed a persistently elevated MP IgG levels which, though expected, may be significant to pathogenesis. We speculate that MP IgG antibodies may predispose to mucositis with repeat exposure to MP or other infectious stimuli. Molecular mimicry due to elevated circulating MP antibodies cross-reacting with the mucous membranes, leading to this reactive phenomenon is a possible etiology. A review of recurrent RIME cases showed that most cases started with an initial MP infection (Table 1) . 6, 8, 9, 11, 12 Future studies could investigate whether persistently elevated antibodies from non-MP pathogens could also increase risk of recurrence. In conclusion, we report two cases of recurrent RIME that introduce influenza A as a new infectious pathogen involved with RIME. We hypothesize that in most recurrent cases the initial pathogen is MP, with subsequent episodes being triggered by a variety of infectious agents. Case series/review (5) Recurrent RIME Yes Not mentioned Brazel et al, 2020 11 Case report (1) Recurrent RIME Unknown as medical records for 1st episode were not obtained Not mentioned Song et al, 2018 12 Case report (1) Frequency and clinical presentation of mucocutaneous disease due to Mycoplasma pneumoniae infection in children with community-acquired pneumonia Mycoplasma pneumoniae-induced rash and mucositis as a syndrome distinct from Stevens-Johnson syndrome and erythema multiforme: a systematic review Reactive infectious mucocutaneous eruption: Mycoplasma pneumoniae-induced rash and mucositis and other parainfectious eruptions Mucositis secondary to Chlamydia pneumoniae infection: expanding the Mycoplasma pneumoniae-induced rash and mucositis concept Chlamydia pneumonia -induced mucositis Two pediatric cases of influenza B-induced rash and mucositis: Stevens-Johnson syndrome or expansion of the Mycoplasma pneumoniae-induced rash with mucositis (MIRM) spectrum? Adenoviral-induced rash and mucositis: expanding the spectrum of reactive infectious mucocutaneous eruption Recurrent reactive infectious mucocutaneous eruption (RIME): insights from a child with three episodes Clinical features of recurrent Mycoplasma pneumoniae-induced rash and mucositis Mycoplasma pneumoniaeinduced rash and mucositis: a recently described entity Rash and mucositis associated with Mycoplasma pneumoniae and Chlamydophila pneumoniae: a recurrence of MIRM? Mycoplasma-induced rash and mucositis in a father and son: a case report Recurrent reactive infectious mucocutaneous eruption (RIME) in two adolescents triggered by several distinct pathogens including SARS-CoV-2 and influenza A